Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Paradigm Medical Industries, Inc. (PDMI) is a U.S.-based enterprise dedicated to the design, production, distribution, and sale of sophisticated medical instruments. These devices are primarily engineered for the timely diagnosis of glaucoma and a variety of other ocular conditions. The company's extensive product range addresses diverse ophthalmic diagnostic requirements. This includes biometric analyzers and A-scans like the P-2000 and P-2500 (which also function as pachymeters), along with P2700 and P37-II A/B scans. Paradigm also provides specialized blood flow analyzers, crucial for identifying and managing glaucoma and other retinal vascular disorders. Its offerings further extend to the P2200 pachymeter and the LD 500 and LD700 autoperimeters. For detailed corneal assessment, they feature the PARAVUE 300, suitable for both diagnostic imaging and contact lens fitting, and the SURVEYOR 500 for in-depth analysis of the cornea and anterior segment. The PARAMAX system, another key product, evaluates the functionality of ganglion cells to help identify individuals at risk of glaucoma. Additionally, Paradigm offers the P60 and P60 ACI ultrasound biomicroscopes, and the PARACAM 1000, a non-contact endothelial microscope. Complementing its hardware, the company also supplies essential software and various accessories. Paradigm Medical Industries was established in 1989 and operates from its headquarters in Salt Lake City, Utah.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.